Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-05-23 | Asarina Pharma | Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Asarina Pharma | Kommuniké från årsstämma i Asarina Pharma AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Asarina Pharma | Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Asarina Pharma | Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Asarina Pharma | Asarina Pharma AB (publ) releases Annual Report 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Asarina Pharma | Asarina Pharma AB (publ) årsredovisning 2022 publicerad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-18 | Asarina Pharma | Asarina Pharma: KALLELSE TILL ÅRSSTÄMMA I ASARINA PHARMA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-18 | Asarina Pharma | Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate Shareholders that wish to participate in the AGM shall be registered in the share register maintained by Euroclear Sweden AB no later than on 11 May 2023 and shall have notified the Company of their intention to participate at the AGM no later than on 15 May 2023. Notice to participate shall be given in writing by e-mail to Nominee-registered shares Shareholders whose shares are registered in the name of a nominee/custodian must register their shares in their own names in order to be entitled to participate in the AGM. Such registration, which may be temporary, must be effected no later than on 15 May 2023 and shareholders must, therefore, instruct their nominees well in advance thereof. Proxy If a shareholder wishes to be represented by proxy, a power of attorney shall be issued to the proxy. The power of attorney is to be in writing, dated and duly signed by the shareholder. If the shareholder is a legal entity, a certificate of incorporation or a corresponding document shall be included with the notification. Please provide the power of attorney in original as well as certificate of incorporation and other documents of authority to the Company to the address mentioned above well in advance before the AGM. If the power of attorney and other documents of authority have not been provided in advance, these documents must be presented at the AGM. Power of attorney forms are available at the Company and on the Company’s website, www.asarinapharma.com and will be sent upon request to any shareholder who states their postal address. Proposal of agenda 1. Opening of the AGM 9. Resolution as to the number of Board members and auditors 11.1 Paul de Potocki (re-election) 11.2 Erin Gainer (re-election) 11.3 Marianne Kock (re-election) 12. Election of chairman of the Board 12.1. Paul de Potocki (re-election) a) with pre-emption rights for the shareholders b) with deviation from the shareholders’ pre-emption rights 16. Closing of the meeting Proposals The Nomination Committee’s proposals (item 2 and Fejl! Henvisningskilde ikke fundet.-Fejl! Henvisningskilde ikke fundet.) that the Board of Directors shall consist of three Board members and no deputy Board members, The Board’s proposals The Board of Directors proposes that no dividend for the financial year 2022 is to be paid. Resolution on authorization for the Board to issue shares, warrants and/or convertible instruments (item 15.a)- 15.b)) 1. a) The AGM authorizes the Board of Directors to, on one or several occasions, during the period up until the next Annual General Meeting, resolve on issuances of shares, warrants and/or convertible instruments with pre-emption rights for the shareholders. Payment may be made in cash, through set-off, by contribution in kind, or otherwise with conditions as set out in Chapter 2, Section 5, second paragraph, items 1-3 and 5 of the Swedish Companies Act. The total number of shares that may be issued, or in the event of an issue of warrants or convertible instruments, any additional shares after conversion or exercise of any warrant, pursuant to the authorization in this item 15.a) shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered Articles of Association. Majority requirements Resolution in accordance with item 15.b) above require approval of at least two thirds (2/3) of the shares represented and votes cast at the AGM. Further information As per the date of the issue of this notice, the total number of shares and votes in the Company are 22,641,409. The Company does not hold any own shares. The annual report, audit report, proxy forms, the Board’s complete proposals as well as complete underlying documentation will be made available by the Company and at the Company’s website at least three weeks before the AGM. The documents will be sent to shareholders who request it and who provide their postal address. The shareholders are reminded of their right of information according to Chapter 7 Section 32 of the Swedish Companies Act. The Company has its registered office in Solna. Processing of personal data For information on how your personal data is processed, see: https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf Solna, April 2023 Asarina Pharma AB (publ) The Board of Directors |
||||
2023-04-01 | Asarina Pharma | Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-01 | Asarina Pharma | Asarina Pharma publicerar positiva resultat från sin fas IIa-studie av Sepranolon i Tourette syndrom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-27 | Asarina Pharma | Asarina Pharma AB (publ) släpper bokslutskommuniké för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-27 | Asarina Pharma | Asarina Pharma AB (publ) releases Year-End Report 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-02 | Asarina Pharma | Asarina Pharma: Sista patientens sista besök i Tourette syndrom-studien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-02 | Asarina Pharma | Asarina Pharma: Last Patient Last Visit for landmark Tourette Syndrome study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-14 | Asarina Pharma | Asarina Pharma: Full rekrytering och sista patienten randomiserad i den viktiga studien om Tourettes syndrom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-14 | Asarina Pharma | Asarina Pharma: Patient recruitment completed in landmark Tourette syndrome study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-06 | Asarina Pharma | Extensive new preclinical study significantly increases the Translatability of Asarina Pharma's findings on key stress mechanism implicated in Tourette Syndrome and OCD | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-06 | Asarina Pharma | Omfattande ny preklinisk studie ökar säkerheten av Asarina Pharmas resultat om en viktig stressmekanism involverad i Tourettes syndrom och OCD | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Asarina Pharma | Asarina Pharma AB (publ) Rapport för andra kvartalet 2022 släppt | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Asarina Pharma | Asarina Pharma AB (publ) Q2 2022 Report released | Rapporter | Ladda ner | Visa Stäng |
|